Treatment class · subcategory · California
Pain Medication denials at external review
When a California health plan denied care in the pain medication class and the enrollee took it to Independent Medical Review, this is what independent physician reviewers decided.
37.3%
- Overturned
- 57 of 153
- Era
- 2021-2025
- Jurisdiction
- California DMHC IMR
- Published class
- Pain Medication
- Median days to decision
- 21
- All years
- 32.1% of 458
What stands out here
computed from this classrising
It has risen over the published record: 25.5% in 2017 against 40.6% in 2023. What drove that is not in this data — the file holds outcomes, not who chose to appeal or how plans changed their own review.
concentrated
54% of these disputes involved orthopedic & musculoskeletal alone (n=82, 36.6% overturned), so the headline figure for pain medication is largely that pairing.
The trend, with its era
computedHover the chart for a year’s counts. Series stops at 2025 — report year 2026 uses a different category vocabulary.
What reviewers relied on
3 validated codesCalifornia requires each published decision to carry “a detailed case summary that includes the specific standards, criteria, and medical and scientific evidence, if any, that led to the case decision” (Health & Safety Code § 1374.33(h)(1)(K)). These are the elements our extraction found in this class, split by how the decision came out.
| What the reviewer relied on | In overturns | In upholds |
|---|---|---|
| the FDA label or approval status | 5%n=57 | 15%n=96 |
| a standardised level-of-care instrument | 5%n=57 | 2%n=96 |
| a California statutory definition | 0%n=57 | 1%n=96 |
Read as description, not instruction. These are patterns in what reviewers wrote, not steps to follow, and no combination of them predicts an outcome. Only codes that cleared the validation gate appear — thirteen did not.
Authorities named in this class
computed- FDA—16
- MCG / Milliman—5
- American Headache Society—2
- American Academy of Orthopaedic Surgeons—1
- American College of Obstetricians and Gynecologists—1
- American College of Rheumatology—1
A rate here is the outcome of decisions that named the authority, not the effect of naming it. Reviewers cite the standard they applied; the citation and the outcome share a cause.
By condition
computed- Overturned — the reviewer did not sustain the denial
- Upheld — the reviewer sustained the denial
- Orthopedic & musculoskeletal36.6%82
- CNS & neuromuscular53.3%30
- Genitourinary & kidney—8
- Digestive & GI—7
- Mental health—4
- Post-surgical complications—4
- Cancer—3
- Genetic disease—3
The specific conditions inside this class
below n=30, no rate is claimed- Back Pain34.4%32
- Other—18
- Vertebral Disc Prob—10
- Chronic Pain Syndrome—8
- Complex Regional Pain Synd/RSD—8
- Hip Problem/Pain—5
- Osteoarthritis—5
- Knee Problem/Pain—4
By review type
computed- Medical Necessity37.1%143
- Experimental/Investigational—10
Medical-necessity review asks whether the care is needed. Experimental/investigational review asks whether it is likely to be more beneficial than standard therapy — a harder statutory test, and the rates show it.
Every figure on this page is conditional on a denial having reached external review. Fewer than 1% of denials are appealed internally at all, so this describes denials that were fought to the end — not denials in general — and it describes California only. Who this does not cover.
Free help, first: the California DMHC Help Center files your Independent Medical Review at no cost — 1-888-466-2219, dmhc.ca.gov.